A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. Stearns, V., O'Neill, A. M., Schneider, B. P., Flockhart, D. A., Skaar, T. C., Liu, M. C., Lohrisch, C. A., Goetz, M. P., Sologuren, C., Sparano, J. A., Villa, D., Silverman, P., Cheema, P. S., Moore, D., Sledge, G. W. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/JCO.2016.34.15_suppl.546

View details for Web of Science ID 000404665400053